Paulson Capital (PLCC) 0.82 $PLCC
Andrews & Springer LLC Has Filed a Class Action Lawsuit on Behalf of Legacy Shareholders of VBI Vaccines, Inc. (f/k/a Paulson Capital Corp.) - VBIV
GlobeNewswire - Wed Nov 26, 9:26PM CST
Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, announces that it has filed a securities class action lawsuit on behalf of legacy shareholders of Paulson Capital Corp. (now referred to as VBI Vaccines, Inc. ("VBI"
(Nasdaq:VBIV) who held shares on October 11, 2013 and were eligible to vote at the Company's Annual Meeting of Shareholders held on November 8, 2013. This lawsuit was filed in the United States District Court, Southern District of New York, Case No. 14-cv-9435.
PLCC: 0.82 (-0.03), VBIV: 3.01 (+0.01)
Variation Biotechnologies and Paulson Capital Announce Completion of Merger
GlobeNewswire - Mon Jul 28, 7:41AM CDT
-- Paulson Capital (Delaware) Corp. Changes Name to VBI Vaccines Inc.
PLCC: 0.82 (-0.03)
Paulson Capital Announces Stockholder Approval of Contemplated Merger With Variation Biotechnologies (US)
GlobeNewswire - Wed Jul 16, 3:53AM CDT
On July 14, 2014, Paulson Capital (Delaware) Corp. (Nasdaq
LCC) (the "Company" held a Special Meeting of Stockholders at which 67.4% of the outstanding shares of the Company's Common Stock were cast and more than 98% of the votes cast were voted in favor of each of a group of proposals related to the contemplated merger with Variation Biotechnologies (US), Inc., a Delaware corporation ("VBI" . The consummation of the merger remains subject to various conditions, including the approval by NASDAQ of the initial listing application of VBI and the approval by the Financial Industry Regulatory Authority ("FINRA" of the change of control as it pertains to the ownership of Company's operating subsidiary, Paulson Investment Company LLC ("PIC" , a FINRA-registered broker-dealer. There can be no assurances that these and other conditions to the consummation of the merger will be satisfied. One of the proposals the stockholders approved permits the Company's Board to effect a reverse stock split of its Common Stock by the ratio required for the price of the Common Stock on the NASDAQ Capital Market to be at least $4.00 per share at the closing of the merger.
PLCC: 0.82 (-0.03)
Paulson Capital (Delaware) Corp. Announces Meeting Date and Record Date for the Special Meeting of Stockholders
GlobeNewswire - Tue Jun 24, 3:50PM CDT
Paulson Capital (Delaware) Corp. (Nasdaq LCC) ("Paulson" today announced that a Special Meeting of Stockholders will be held on July 14, 2014, at 1:00 p.m., PDT, at the offices of Holland & Knight LLP, 111 S.W. Fifth Avenue, 2300 U.S. Bancorp Tower, Portland, Oregon 97204. Holders of record of Paulson's common stock, as reflected on the stock transfer books of Paulson, at the close of business on June 25, 2014 (the "Record Date" , will be entitled to notice of and to vote at the meeting.
PLCC: 0.82 (-0.03), USB: 45.07 (-0.05)
Andrews & Springer LLC Has Filed a Class Action Lawsuit on Behalf of Legacy Shareholders of VBI Vaccines, Inc. (f/k/a Paulson Capital Corp.) - VBIV
GlobeNewswire - Wed Nov 26, 9:26PM CST
Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, announces that it has filed a securities class action lawsuit on behalf of legacy shareholders of Paulson Capital Corp. (now referred to as VBI Vaccines, Inc. ("VBI"
(Nasdaq:VBIV) who held shares on October 11, 2013 and were eligible to vote at the Company's Annual Meeting of Shareholders held on November 8, 2013. This lawsuit was filed in the United States District Court, Southern District of New York, Case No. 14-cv-9435. PLCC: 0.82 (-0.03), VBIV: 3.01 (+0.01)
Variation Biotechnologies and Paulson Capital Announce Completion of Merger
GlobeNewswire - Mon Jul 28, 7:41AM CDT
-- Paulson Capital (Delaware) Corp. Changes Name to VBI Vaccines Inc.
PLCC: 0.82 (-0.03)
Paulson Capital Announces Stockholder Approval of Contemplated Merger With Variation Biotechnologies (US)
GlobeNewswire - Wed Jul 16, 3:53AM CDT
On July 14, 2014, Paulson Capital (Delaware) Corp. (Nasdaq
LCC) (the "Company" held a Special Meeting of Stockholders at which 67.4% of the outstanding shares of the Company's Common Stock were cast and more than 98% of the votes cast were voted in favor of each of a group of proposals related to the contemplated merger with Variation Biotechnologies (US), Inc., a Delaware corporation ("VBI" . The consummation of the merger remains subject to various conditions, including the approval by NASDAQ of the initial listing application of VBI and the approval by the Financial Industry Regulatory Authority ("FINRA" of the change of control as it pertains to the ownership of Company's operating subsidiary, Paulson Investment Company LLC ("PIC" , a FINRA-registered broker-dealer. There can be no assurances that these and other conditions to the consummation of the merger will be satisfied. One of the proposals the stockholders approved permits the Company's Board to effect a reverse stock split of its Common Stock by the ratio required for the price of the Common Stock on the NASDAQ Capital Market to be at least $4.00 per share at the closing of the merger. PLCC: 0.82 (-0.03)
Paulson Capital (Delaware) Corp. Announces Meeting Date and Record Date for the Special Meeting of Stockholders
GlobeNewswire - Tue Jun 24, 3:50PM CDT
Paulson Capital (Delaware) Corp. (Nasdaq
LCC) ("Paulson" today announced that a Special Meeting of Stockholders will be held on July 14, 2014, at 1:00 p.m., PDT, at the offices of Holland & Knight LLP, 111 S.W. Fifth Avenue, 2300 U.S. Bancorp Tower, Portland, Oregon 97204. Holders of record of Paulson's common stock, as reflected on the stock transfer books of Paulson, at the close of business on June 25, 2014 (the "Record Date" , will be entitled to notice of and to vote at the meeting. PLCC: 0.82 (-0.03), USB: 45.07 (-0.05)
